Table 2.
Univariate analyses result for disease-free survival.
| Univariate analysis | ||||
|---|---|---|---|---|
| N=38 | Hazard ratio | 95% CI | P value | |
| Age | ||||
| ≤ 60 > 60 |
21 17 |
4.6 1 |
0.79-87.5 | 0.16 |
| Tumor size | ||||
| T1a/T1b T1c |
10 28 |
1 0.81 |
0.18-5.8 | 0.80 |
| Surgery | ||||
| Lumpectomy Mastectomy |
22 16 |
1 2.3 |
0.50-11.6 | 0.29 |
| Adjuvant chemotherapy | ||||
| Yes No |
24 14 |
1 3.7 |
0.74-17.1 | 0.11 |
| Adjuvant therapy | ||||
| Yes No |
27 11 |
1 7.4 |
1.6-37.8 | 0.0096* |
| Histological grade | ||||
| 1/2 3 |
9 29 |
1 0.54 |
0.13-2.7 | 0.41 |
| Nuclear grade | ||||
| 1/2 3 |
7 31 |
1 0.12 |
0.023-0.54 | 0.0055* |
| Estrogen receptor | ||||
| 0 less than 1% |
35 3 |
1 2.1 |
0.11-12.7 | 0.48 |
| Progesterone receptor | ||||
| 0 less than 1% |
34 4 |
1 1.2 |
0.064-7.1 | 0.86 |
| HER2 | ||||
| 0 1+/2+ and ISH negative |
28 10 |
1 9.0 |
1.9-62.8 | 0.0090* |
Of the 42 patients with Stage I TNBC, 38 were analyzed, excluding four patients whose recurrence time was unclear in the medical records.
The reference for the hazard ratio for each item was set at 1. Factors with significant differences are indicated by asterisks. Patients were divided into HER2-0 or HER2-low (1+/2+ and ISH negative) according to HER2 status. HR, hazard ratio; CI, confidence interval.